Phase 1/2 open-label trial to assess the safety and preliminary efficacy of (177)Lu-OPS201 as peptide receptor radionuclide therapy in patients with somatostatin receptor-positive, progressive neuroendocrine tumors Meeting Abstract


Authors: Nicolas, G.; Bodei, L.; Baum, R.; Herrmann, K.; Lassmann, M.; Hicks, R.; Navalkissoor, S.; Haug, A.; Oberwittler, H.; Wang, T.; Wild, D.
Abstract Title: Phase 1/2 open-label trial to assess the safety and preliminary efficacy of (177)Lu-OPS201 as peptide receptor radionuclide therapy in patients with somatostatin receptor-positive, progressive neuroendocrine tumors
Meeting Title: 10th Annual Meeting of the North American Neuroendocrine Tumor Society (NANETS)
Journal Title: Pancreas
Volume: 47
Issue: 3
Meeting Dates: 2017 Oct 19-21
Meeting Location: Philadelphia, PA
ISSN: 0885-3177
Publisher: Lippincott Williams & Wilkins  
Date Published: 2018-03-01
Start Page: 349
Language: English
ACCESSION: WOS:000426086300079
PROVIDER: wos
DOI: 10.1097/MPA.0000000000000997
Notes: Meeting Abstract -- Source: Wos
Altmetric
Citation Impact
MSK Authors
  1. Lisa   Bodei
    108 Bodei